Periscope Capital’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

Periscope Capital’s Portfolio RVPHW Stock Details RVPHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-90,600	Closed	-$8K	–	246
2020 Q1	$8K	Hold	90,600	–	–	﹤0.01%	239
2019 Q4	$16K	Hold	90,600	–	–	﹤0.01%	237
2019 Q3	$18K	Hold	90,600	–	–	﹤0.01%	224
2019 Q2	$20K	Buy	90,600 +50,300	+125%	+$10.1K	﹤0.01%	205
2019 Q1	$6K	Hold	40,300	–	–	﹤0.01%	170
2018 Q4	$13K	Buy	+40,300	New	+$12.9K	﹤0.01%	176

Other funds holding RVPHW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Periscope Capital's RVPHW Position: Q2 2020 in Review

Periscope Capital sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q2 2020, closing a stake of 90,600 shares — an estimated $8K sold.

Periscope Capital first reported a position in RVPHW in Q4 2018 and held it in 6 quarters. The position peaked at $20K in Q2 2019. 17 funds tracked by Wall St. Rank hold RVPHW as of Q2 2020.

Periscope Capital reported no remaining Reviva Pharmaceuticals Warrants position as of Q2 2020 after selling out during the quarter.
Periscope Capital sold 90,600 Reviva Pharmaceuticals Warrants shares in Q2 2020, an estimated $8K.
Periscope Capital first reported a position in Reviva Pharmaceuticals Warrants in Q4 2018 and held it in 6 quarters.
Periscope Capital's Reviva Pharmaceuticals Warrants position peaked at $20K in Q2 2019.
17 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q2 2020.

Based on Periscope Capital's 13F filing for Q2 2020, filed 11 Aug 2020.